Read by QxMD icon Read

Cardiovascular nanomedicine

Kei Xian Tan, Sharadwata Pan, Jaison Jeevanandam, Michael K Danquah
Cardiovascular ailments are the foremost trigger of death in the world today, including myocardial infarction and ischemic heart diseases. To date, extraordinary measures have been prescribed, from the perspectives of both conventional medical therapies and surgeries, to enforce cardiac cell regeneration post cardiac traumas, albeit with limited long-term success. The prospects of successful heart transplants are also grim, considering exorbitant costs and unavailability of suitable donors in most cases. From the perspective of cardiac revascularization, use of nanoparticles and nanoparticle mediated targeted drug delivery have garnered substantial attention, attributing to both active and passive heart targeting, with enhanced target specificity and sensitivity...
March 10, 2019: International Journal of Pharmaceutics
M D Mauricio, S Guerra-Ojeda, P Marchio, S L Valles, M Aldasoro, I Escribano-Lopez, J R Herance, M Rocha, J M Vila, V M Victor
Nanotechnology has had a significant impact on medicine in recent years, its application being referred to as nanomedicine. Nanoparticles have certain properties with biomedical applications; however, in some situations, they have demonstrated cell toxicity, which has caused concern surrounding their clinical use. In this review, we focus on two aspects: first, we summarize the types of nanoparticles according to their chemical composition and the general characteristics of their use in medicine, and second, we review the applications of nanoparticles in vascular alteration, especially in endothelial dysfunction related to oxidative stress...
2018: Oxidative Medicine and Cellular Longevity
Mehdi Rezaee, Behzad Behnam, Maciej Banach, Amirhossein Sahebkar
With unique characteristics such as high surface area, capacity of various functionalization, low weight, high conductivity, thermal and chemical stability, and free radical scavenging, carbon nanomaterials (CNMs) such as carbon nanotubes (CNTs), fullerene, graphene (oxide), carbon nanohorns (CNHs), and their derivatives have increasingly been utilized in nanomedicine and biomedicine. On the one hand, owing to ever-increasing applications of CNMs in technological and industrial fields as well as presence of combustion-derived CNMs in the ambient air, the skepticism has risen over the adverse effects of CNMs on human being...
October 17, 2018: Biotechnology Advances
Artur Y Prilepskii, Anna F Fakhardo, Andrey S Drozdov, Vasiliy V Vinogradov, Ivan P Dudanov, Alexander A Shtil, Petr P Bel'tyukov, Alexey M Shibeko, Ekaterina M Koltsova, Dmitry Y Nechipurenko, Vladimir V Vinogradov
Mortality and disabilities as outcomes of cardiovascular diseases are primarily related to blood clotting. Optimization of thrombolytic drugs is aimed at the prevention of side effects (in particular, bleeding) associated with a disbalance between coagulation and anticoagulation caused by systemically administered agents. Minimally invasive and efficient approaches to deliver the thrombolytic agent to the site of clot formation are needed. Herein, we report a novel nanocomposite prepared by heparin-mediated cross-linking of urokinase with magnetite nanoparticles (MNPs@uPA)...
October 31, 2018: ACS Applied Materials & Interfaces
Cen Yan, Xiao-Jiang Quan, Ying-Mei Feng
Myocardial infarction (MI) is the most severe ischemic heart disease and directly leads to heart failure till death. Target molecules have been identified in the event of MI including increasing angiogenesis, promoting cardiomyocyte survival, improving heart function and restraining inflammation and myocyte activation and subsequent fibrosis. All of which are substantial in cardiomyocyte protection and preservation of cardiac function. To modulate target molecule expression, virus and non-virus-mediated gene transfer have been investigated...
October 3, 2018: Current Gene Therapy
Iwona Cicha, Cédric Chauvierre, Isabelle Texier, Claudia Cabella, Josbert M Metselaar, János Szebeni, László Dézsi, Christoph Alexiou, François Rouzet, Gert Storm, Erik Stroes, Donald Bruce, Neil MacRitchie, Pasquale Maffia, Didier Letourneur
Cardiovascular diseases (CVD) account for nearly half of all deaths in Europe and almost 30% of global deaths. Despite the improved clinical management, cardiovascular mortality is predicted to rise in the next decades due to the increasing impact of aging, obesity, and diabetes. The goal of emerging cardiovascular nanomedicine is to reduce the burden of CVD using nanoscale medical products and devices. However, the development of novel multicomponent nano-sized products poses multiple technical, ethical, and regulatory challenges, which often obstruct their road to successful approval and use in clinical practice...
November 1, 2018: Cardiovascular Research
Chuying Ma, Ethan Gerhard, Di Lu, Jian Yang
Leveraging the multifunctional nature of citrate in chemistry and inspired by its important role in biological tissues, a class of highly versatile and functional citrate-based materials (CBBs) has been developed via facile and cost-effective polycondensation. CBBs exhibiting tunable mechanical properties and degradation rates, together with excellent biocompatibility and processability, have been successfully applied in vitro and in vivo for applications ranging from soft to hard tissue regeneration, as well as for nanomedicine designs...
September 2018: Biomaterials
Jia Yao, Yuan Cheng, Min Zhou, Sheng Zhao, Shichao Lin, Xiaoyu Wang, Jiangjiexing Wu, Sirong Li, Hui Wei
Reactive oxygen species (ROS)-induced oxidative stress is linked to various diseases, including cardiovascular disease and cancer. Though highly efficient natural ROS scavenging enzymes have been evolved, they are sensitive to environmental conditions and hard to mass-produce. Therefore, enormous efforts have been devoted to developing artificial enzymes with ROS scavenging activities. Among them, ROS scavenging nanozymes have recently attracted great interest owing to their enhanced stability, multi-functionality, and tunable activity...
March 21, 2018: Chemical Science
Ailar Nakhlband, Morteza Eskandani, Yadollah Omidi, Nazli Saeedi, Samad Ghaffari, Jaleh Barar, Alireza Garjani
Introduction: Cardiovascular diseases (CVDs) is recognized as the leading cause of mortality worldwide. The increasing prevalence of such disease demands novel therapeutic and diagnostic approaches to overcome associated clinical/social issues. Recent advances in nanotechnology and biological sciences have provided intriguing insights to employ targeted Nanomachines to the desired location as imaging, diagnosis, and therapeutic modalities. Nanomedicines as novel tools for enhanced drug delivery, imaging, and diagnosis strategies have shown great promise to combat cardiovascular diseases...
2018: BioImpacts: BI
Mukul Ashtikar, Matthias G Wacker
Today, many of the newly developed pharmaceuticals and medical devices take advantage of nanotechnology and with a rising incidence of chronic diseases such as diabetes and cardiovascular disease, the number of patients afflicted globally with non-healing wounds is growing. This has created a requirement for improved therapies and wound care. However, converting the strategies applied in early research into new products is still challenging. Many of them fail to comply with the market requirements. This review discusses the legal and scientific challenges in the design of nanomedicines for wound healing...
April 2018: Advanced Drug Delivery Reviews
Rahul Mittal, Vasanti M Jhaveri, Hannah S McMurry, Sae-In Samantha Kay, Kyle J Sutherland, Lin Nicole, Jeenu Mittal, Rahul Dev Jayant
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Due to the significant impact of CVD on humans, there is a need to develop novel treatment modalities tailored to major classes of cardiac diseases including hypertension, coronary artery disease, cardiomyopathies, arrhythmias, valvular disease and inflammatory diseases. In this article, we discuss recent advancements regarding development of therapeutic strategies based on stem cells, aptamers, exosomes, drug-eluting and dissolvable stents, immunotherapy and nanomedicine for the treatment of CVD...
February 15, 2018: Artificial Cells, Nanomedicine, and Biotechnology
Maria Sofia Falzarano, Cristina Flesia, Roberta Cavalli, Caterina Guiot, Alessandra Ferlini
BACKGROUND: Genetic alterations cause Hereditary Diseases (HDs) with a wide range of incidences. Some, like cystic fibrosis, occur frequently (1/1,000 newborns), whilst others, such as Pompe disease and other metabolic disorders are very rare (1/100,000 newborns). They are well under the threshold of 1/3,000, denoted by the European Community as Rare Diseases (RDs). Genetic alterations are also associated with multifactorial disorders like diabetes, and underline both somatic and germline mutations in cancer...
2018: Current Pharmaceutical Design
Cecilia Ka Wing Chan, Lei Zhang, Chak Kwong Cheng, Hongrong Yang, Yu Huang, Xiao Yu Tian, Chung Hang Jonathan Choi
Atherosclerosis, driven by chronic inflammation of the arteries and lipid accumulation on the blood vessel wall, underpins many cardiovascular diseases with high mortality rates globally, such as stroke and ischemic heart disease. Engineered bio-nanomaterials are now under active investigation as carriers of therapeutic and/or imaging agents to atherosclerotic plaques. This Review summarizes the latest bio-nanomaterial-based strategies for managing atherosclerosis published over the past five years, a period marked by a rapid surge in preclinical applications of bio-nanomaterials for imaging and/or treating atherosclerosis...
January 2018: Small
Kye S Kim, Chul Gyu Song, Peter M Kang
SIGNIFICANCE: Nanomedicine is an application of nanotechnology that provides solutions to unmet medical challenges. The unique features of nanoparticles, such as their small size, modifiable components, and diverse functionality, make them attractive and suitable materials for novel diagnostic, therapeutic, or theranostic applications. Cardiovascular diseases (CVDs) are the major cause of noncommunicable illness in both developing and developed countries. Nanomedicine offers novel theranostic options for the treatment of CVDs...
January 30, 2018: Antioxidants & Redox Signaling
Qianjun He
Gas therapy is an emerging and promising field, utilizing the unique therapeutic effects of several kinds of gases (NO, CO, H2 S and H2 ) towards many major diseases, including cancer and cardiovascular diseases, and it is also facing challenges relating to enhancing gas therapy efficacy and avoiding gas poisoning risks. Here, we have proposed a new concept for precision gas therapy using a nanomedicine strategy to overcome the challenges. In this perspective, we have addressed a series of existing and potential solutions from the point of view of nanomedicine, and conveyed a collection of opinions about future expandable research into precision gas therapy...
October 24, 2017: Biomaterials Science
Kannan Vaidyanathan, Sandhya Gopalakrishnan
BACKGROUND: Atherosclerosis is a chronic inflammatory condition causing very high morbidity and mortality. It is characterized by accumulation of plaques within arteries. Nanomedicine is an emerging field of medicine utilizing nanotechnology for advanced imaging and therapy. Nanomedicine has led to significant developments in the field of cardiovascular diseases, including atherosclerosis. Many nanoformulations have been developed with anti-atherosclerotic effects. Nanomedicine tools have been used in the imaging of atherosclerosis...
2017: Cardiovascular & Hematological Disorders Drug Targets
Yin Dou, Yue Chen, Xiangjun Zhang, Xiaoqiu Xu, Yidan Chen, Jiawei Guo, Dinglin Zhang, Ruibing Wang, Xiaohui Li, Jianxiang Zhang
Atherosclerosis is the leading cause of many fatal cardiovascular and cerebrovascular diseases. Whereas nanomedicines are promising for targeted therapy of atherosclerosis, great challenges remain in development of effective, safe, and translational nanotherapies for its treatment. Herein we hypothesize that non-proinflammatory nanomaterials sensitive to low pH or high reactive oxygen species (ROS) may serve as effective platforms for triggerable delivery of anti-atherosclerotic therapeutics in cellular and tissue microenvironments of inflammation...
October 2017: Biomaterials
Alexander N Kharlamov, John A Feinstein, John A Cramer, John A Boothroyd, Ekaterina V Shishkina, Vladimir Shur
AIM: The safety options in nanomedicine raise an issue of the optimal niche at the real-world clinical practice. METHODS: This is an observational prospective cohort analysis of the 5-year clinical outcomes at the intention-to-treat population (nano vs ferro vs stenting; n = 180) of NANOM first-in-man trial (NCT01270139). RESULTS: Mortality (6 vs 9 vs 10 cases of cardiac death in groups, p < 0.05), major adverse cardiovascular events (14...
July 2017: Future Cardiology
Changsun Kang, Sian Gwon, ChulGyu Song, Peter M Kang, Seong-Cheol Park, Jongho Jeon, Do Won Hwang, Dongwon Lee
A thrombus (blood clot) is formed in injured vessels to maintain the integrity of vasculature. However, obstruction of blood vessels by thrombosis slows blood flow, leading to death of tissues fed by the artery and is the main culprit of various life-threatening cardiovascular diseases. Herein, we report a rationally designed nanomedicine that could specifically image obstructed vessels and inhibit thrombus formation. On the basis of the physicochemical and biological characteristics of thrombi such as an abundance of fibrin and an elevated level of hydrogen peroxide (H2 O2 ), we developed a fibrin-targeted imaging and antithrombotic nanomedicine, termed FTIAN, as a theranostic system for obstructive thrombosis...
June 27, 2017: ACS Nano
Jie Tang, Rui Kuai, Wenmin Yuan, Lindsey Drake, James J Moon, Anna Schwendeman
Synthetic high-density lipoprotein nanoparticles (sHDL) are a valuable class of nanomedicines with established animal safety profile, clinical tolerability and therapeutic efficacy for cardiovascular applications. In this study we examined how the scavenger receptor B-I-mediated (SR-BI) tumor-targeting ability of sHDL, long plasma circulation half-life, and small particle size (9.6±0.2nm) impacted sHDL accumulation in SR-BI positive colorectal carcinoma cells, 3D tumor spheroids, and in vivo xenografts. We compared tumor accumulation of sHDL with that of liposomes (LIP, 130...
August 2017: Nanomedicine: Nanotechnology, Biology, and Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"